Background: Delays in treatments are frequent in real-world lymphoma management. This study evaluates the impact of diagnosis-to-treatment intervals (DTIs) and first inter-cycle delay (IcD) on outcomes in patients with Hodgkin lymphoma (HL) receiving ABVD chemotherapy. Methods: We retrospectively analyzed 137 patients with classical HL treated with ABVD at a single institution between 2015 and 2022. Results: The median age was 34 years (range: 18–73), and 62% were male. The median DTI was 14 days, with 24.1% of patients experiencing a delay of >7 days between the first and second chemotherapy cycles. The most frequent reason for delay was neutropenia, observed in 69% of delayed cases. Neither DTI nor IcD was significantly associated with PFS or OS. Multivariate analysis identified elevated beta-2 microglobulin as an independent predictor of both inferior PFS and OS. Conclusions: This is the first study to evaluate both DTI and first IcD as independent prognostic factors in HL. Modest delays in treatment initiation or early cycle administration did not negatively affect survival. Timely but flexible scheduling of ABVD may be appropriate in HL. Prospective studies are warranted in the era of novel therapeutic agents.

Lithium, which is widely used in mood disorders, has several side effects. Lymphocytosis is a rare side effect. The patient was a young man in his twenties. The patient referred from psychiatry for persistent lymphocytosis. After the initial evaluation, the possible relationship between lithium and lymphocyte levels was considered. The diagnosis of lymphocytosis secondary to lithium intake can only be made with the elimination of other possible causes of lymphocytosis. Therefore, possible viral infections, possible drug interactions, possible systemic diseases, and malignancies were evaluated and eliminated. After evaluation, a correlation was found between lithium blood level and lymphocyte count. The patient started to be followed up.